

COMMENCEMENT 2004

SUNY Upstate Medical University President Gregory L. Eastwood, MD, awarded degrees to 151 students from the College of Medicine, who are beginning residencies across the nation. (Alumni received a complete list of residency placements in a recent mailing from the Alumni Office.)

Carol Baldwin, a breast cancer survivor who founded a breast cancer research fund, and Brian J. Druker, MD, a hematologist/oncologist whose research led to the development of FDA-approved cancer drug Gleevec, addressed graduates and received honorary

degrees at SUNY Upstate Medical University's 2004 Commencement Ceremony Sunday, May 16 in the John H. Mulroy Civic Center Crouse Hinds Theater in Syracuse.



Carol Baldwin

first of a new breed of drug compounds that are reverse-engineered to disrupt abnormal molecular processes. Druker is the director of the Cancer Institute Leukemia Center at the Oregon Health Sciences University (OHSU) in Portland, professor of medicine in OHSU's division of hematology and medical oncology, an investigator at the Howard Hughes Medical Institute and program leader in hematologic malignancies at the OHSU Cancer Institute. He holds a joint appointment in OHSU's Department of Cell and Developmental Biology.



Far left: Brian J. Druker, MD

Near left: Chris Bannerman, MD '04
and Donna Thomas, MD '04

degrees at SUNY Upstate Medical University's 2004 Commencement Ceremony Sunday, May 16 in the John H. Mulroy Civic Center Crouse Hinds Theater in Syracuse.

Diagnosed with breast cancer in 1990 and treated at SUNY Upstate's University Hospital, Baldwin turned her personal medical challenge into a powerful and widespread crusade to accelerate the search for a cure for breast cancer. In 1996, she founded the Carol M. Baldwin Breast Cancer Research Fund Inc. which exclusively funds research at SUNY Upstate Medical University and SUNY Stony Brook. Since 1996 her organization has awarded a combined \$2.5 million for breast cancer research to these two SUNY campuses.

Druker is recognized for leading the molecular research that inspired the development of Gleevec and for his efforts to convince the pharmaceutical industry to invest in molecularly targeted drugs like Gleevec, the



Dr. Barry Bergh, left, hoods valedictorian Evan Grossman, MD '04